Phase Ib/II Trial of Lurbinectedin Plus Irinotecan in Patients With Advanced Solid Tumors

May 29-31, 2020; Online at meetings.asco.org/am
Combined treatment with lurbinectedin and irinotecan yields promising early antitumor activity in small-cell lung cancer, with an ORR of 69.2% in 13 evaluable patients.
Format: Microsoft PowerPoint (.ppt)
File Size: 232 KB
Released: June 4, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

In this slideset from Clinical Care Options, a panel of international experts review the role of immunotherapy for patients with endometrial cancer.

person default Mansoor Raza Mirza, MD Bradley J. Monk, MD, FACS, FACOG Prof Isabelle Ray Coquard Released: March 2, 2021

Expert faculty reviews key clinical trials in relapsed extensive-stage small-cell lung cancer from the 2020 World Conference on Lung Cancer, from Clinical Care Options (CCO)

person default Nicolas Girard, MD, PhD Released: March 1, 2021

Domenica Lorusso, MD, PhD, on the molecular reclassification of endometrial cancers and key ongoing immunotherapy trials, from Clinical Care Options (CCO)

Domenica Lorusso, MD, PhD Released: February 25, 2021

Podcast episode with expert insights on new data from WCLC 2020 helping to improve outcomes for patients with early-stage lung cancer, from Clinical Care Options (CCO)

Jamie E. Chaft, MD Released: February 24, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue